A comparison of next-generation sequencing analysis methods for cancer xenograft samples.

Abstract

The application of next-generation sequencing (NGS) technology in cancer is influenced by the quality and purity of tissue samples. This issue is especially critical for patient-derived xenograft (PDX) models, which have proven to be by far the best preclinical tool for investigating human tumor biology, because the sensitivity and specificity of NGS analysis in xenograft samples would be compromised by the contamination of mouse DNA and RNA. This definitely affects downstream analyses by causing inaccurate mutation calling and gene expression estimates. The reliability of NGS data analysis for cancer xenograft samples is therefore highly dependent on whether the sequencing reads derived from the xenograft could be distinguished from those originated from the host. That is, each sequence read needs to be accurately assigned to its original species. Here, we review currently available methodologies in this field, including Xenome, Disambiguate, bamcmp and pdxBlacklist, and provide guidelines for users.

• Authors: Wentao Dai, Jixiang Liu, Quanxue Li, Wei Liu, Yi-Xue Li, Yuan-Yuan Li
• Journal: Journal of genetics and genomics = Yi chuan xue bao (J Genet Genomics) Vol. 45 Issue 7 Pg. 345-350 (07 20 2018) ISSN: 1673-8527 [Print] China
• PMID: 30055875 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2018. Published by Elsevier Ltd.

Topics

• Animals
• Cell Transformation, Neoplastic
• High-Throughput Nucleotide Sequencing (methods)
• Humans
• Neoplasms (genetics, pathology)